In a yesterdays’ CNBC “Squawk Box” program, Corvex Management’s Keith Meister was a guest and he shared his views on the current and the future market state.
Keep Reading →
April 3 - Hedge Funds, News - Comments
Seth Klarman, a hedge fund billionaire some call the next Warren Buffett, wrote a sobering letter warning his investors of the economic impact of global tension, rising debt and...
Keep Reading →
January 22 - Hedge Funds, Insider Trading - Comments
Rock Springs Capital Management is a Baltimore-based hedge fund founded in February 2013 by Kris Jenner. Prior to that, Jenner had spent 14 years working at T.
Keep Reading →
February 24 - Hedge Funds, News - Comments
With all of the heat generated by this biotech and its stock, it pays to pay attention to what Celgene Corporation (NASDAQ:CELG) says.
Keep Reading →
September 16 - News - Comments
A couple months may not seem like a long time, but when you're diagnosed with pancreatic cancer, the prospect of a few months makes a huge difference.
Keep Reading →
September 13 - Dividend Stocks, News - Comments
Earlier this month, I wrote an article explaining that I liked Incyte Corporation (NASDAQ:INCY) on the basis of the blockbuster potential of its only approved drug, Jakafi...
Keep Reading →
September 6 - News - Comments
The big biotech announced on Thursday that updated results from its phase 3 study of Pomalyst in treating relapsed or refractory multiple myeloma had been published online in ...
Keep Reading →
September 5 - News - Comments
It should come as no surprise to anyone that the Food and Drug Administration granted a priority review for Pharmacyclics, Inc.
Keep Reading →
September 3 - News - Comments
"Bubble" can be a provocative word in investing circles. Think of all that comes to mind when you hear it -- perhaps other words like over-hyped, overvalued, risky, etc.
Keep Reading →
August 27 - News - Comments
At the end of June, Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) announced that it had rejected an offer from Amgen, Inc.
Keep Reading →
August 24 - News - Comments
In after hours trading on April 18, a few hours after the release of my previous article focusing on Exelixis, Inc.
Keep Reading →
August 23 - News - Comments
Earlier this month, biotech powerhouse Celgene Corporation (NASDAQ:CELG) announced that the European Commission approved the combinational therapy of pomalidomide, known in the...
Keep Reading →
August 22 - News - Comments
About 15,680 Americans are diagnosed with chronic lymphocytic leukemia, or CLL, and approximately 5,000 new cases of mantle cell lymphoma, or MCL, occur in the U.S.
Keep Reading →
August 21 - News - Comments
Incyte Corporation (NASDAQ:INCY) today announced positive results from a phase 2 study of its drug Jakafi in treating refractory metastatic pancreatic cancer.
Keep Reading →
August 21 - News - Comments
One of the traits an investor should have is an ability to display forward-thinking. It is always better to see whats next instead of what has already happened.
Keep Reading →
August 12 - News - Comments
With the SPDR S&P Biotech Index up 40% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
Keep Reading →
August 12 - News - Comments
2013 has been a banner year for biotech IPOs.
Keep Reading →
August 7 - News - Comments
The investing waters can get pretty choppy from time to time with a developmental stage company. A look at the five-year chart of Momenta Pharmaceuticals, Inc.
Keep Reading →
August 2 - News - Comments
Astex Pharmaceuticals, Inc. (NASDAQ:ASTX) announced its second-quarter financial results on Thursday prior to the market open.
Keep Reading →
August 2 - News - Comments
Three of the biggest names in biotechnology have reported earnings, and their quarters involved very important drug-related information for investors.
Keep Reading →
July 29 - News - Comments
We are in the midst of the earnings season, my favorite time of the year.
Keep Reading →
July 29 - News - Comments
Multiple myeloma is a cancer of plasma cells, a type of white blood cell present in bone marrow.
Keep Reading →
July 26 - News - Comments
Celgene Corporation (NASDAQ:CELG) did it again. Investors have grown accustomed to the company reporting solid numbers with its earnings announcements.
Keep Reading →
July 26 - News - Comments
The first half of 2013 has seen remarkable growth in the biotech sector, with the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ:IBB) up >40% YTD. The industry continues to...
Keep Reading →
July 24 - News - Comments
Celgene Corporation (NASDAQ:CELG) fell 2.6% on Thursday after disappointing clinical data for its blood cancer drug Revlimid.
Keep Reading →
July 23 - News - Comments
Celgene Corporation (NASDAQ:CELG) fell 2.6% on Thursday after disappointing clinical data for its blood cancer drug Revlimid.
Keep Reading →
July 22 - News - Comments
In an industry where buyouts are commonplace and small-cap biotechs burn through cash rapidly, optimizing operating cash flow can be essential to a company's financial health.
Keep Reading →
July 19 - News - Comments
Celgene Corporation (NASDAQ:CELG) has emerged as the leading treatment provider for blood cancer.
Keep Reading →
July 19 - News - Comments
Early this morning, Celgene Corporation (NASDAQ:CELG) announced that it was discontinuing the phase 3 ORIGIN Trial evaluating Revlimid (lenalidomide) in B-Cell chronic lymphomatic...
Keep Reading →
July 18 - News - Comments
Celgene Corporation (NASDAQ:CELG) surged 7% on Thursday, July 11, 2013 on news that the Phase III trials of Revlimid /dexamethasone combination showed that it could be an initial...
Keep Reading →
July 18 - News - Comments
In July 2012, the Food and Drug Administration Safety and Innovation Act was signed into law; and little did we know at the time, but the drug development process was about to...
Keep Reading →
July 12 - News - Comments
Good news seems to find its way to Celgene Corporation (NASDAQ:CELG)'s door frequently these days.
Keep Reading →
July 11 - News - Comments
Recently Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) rejected a $10 billion takeover offer from Amgen, Inc. (NASDAQ:AMGN).
Keep Reading →
July 10 - News - Comments
It’s been a healthy year-to-date for the biotech sector, with the space logging huge gains above and beyond those of the broad based market.
Keep Reading →
July 10 - News - Comments
This year, the North American players in the biotechnology industry are expected to spend $15 billion.
Keep Reading →
July 5 - News - Comments
Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) has recently experienced a significant jump of nearly 51.3% in only one trading day from $86.82 per share to $131.30 per share.
Keep Reading →
July 5 - News - Comments
As the first half of 2013 ends, let's look at the year-to-date top performing (and profitable) large cap stocks.
Keep Reading →
July 5 - News - Comments
Recently, Amgen, Inc. (NASDAQ:AMGN) made a surprisingly low offer to acquire the pharmaceutical company Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX).
Keep Reading →
July 3 - News - Comments
That's the message from Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) over the weekend after Amgen, Inc. (NASDAQ:AMGN) made an unsolicited offer to buy the company.
Keep Reading →
July 2 - News - Comments
Investing in biotech companies isn't without its challenges, but it doesn't have to be a shot in the dark, either.
Keep Reading →
June 27 - News - Comments
Let me preface this by saying that investing in the biotech sector can sometimes be nothing more than speculating.
Keep Reading →
June 27 - News - Comments
Global equity markets have been rocked recently as fears of rising interest rates and tightening monetary possible make their way into the minds of the street.
Keep Reading →
June 26 - News - Comments
Dividend stocks are hard to come by in the biotech space.
Keep Reading →
June 26 - News - Comments
A double-digit drop for Amgen, Inc. (NASDAQ:AMGN) stock over the past couple of months has likely left a bad taste in the mouths of shareholders.
Keep Reading →
June 25 - News - Comments
Which biotech companies are the best-run? That could be a difficult question to answer, since there are many perspectives on what constitutes a well-run company.
Keep Reading →
June 24 - News - Comments
Almost all retirement investment strategies advocate generating a steady income from dividend payments from well-established, safe stocks.
Keep Reading →
June 18 - News - Comments
It's understandably very tempting for people with inside information to trade biotech stocks.
Keep Reading →
June 17 - News - Comments
Biotech stocks can provide astronomical returns but also depressing losses.
Keep Reading →
June 14 - News - Comments
This series, brought to you by Yahoo! Finance, looks at which upgrades and downgrades make sense, and which ones investors should act on.
Keep Reading →
June 13 - News - Comments
Celgene Corporation (NASDAQ:CELG) shares have soared more than 46% so far in 2013.
Keep Reading →
June 12 - News - Comments
